NEW REALITIES IN THE TREATMENT OF DISSEMINATED SKIN MELANOMA WITH BRAF MUTATION
- Authors: Abramov M.E1, Gordeeva O.O1, Borisova E.I1, Gutorov S.L1, Vyshinskaya G.V1
-
Affiliations:
- Issue: No 17 (2016)
- Pages: 82-86
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289369
- ID: 289369
Cite item
Abstract
Full Text
About the authors
M. E Abramov
FSBI "RORC n.a. N.N. Blokhin" of RMH PhD, Senior Researcher at the Department of Chemotherapy and Combined Therapy of Malignant Tumors Moscow
O. O Gordeeva
FSBI "RORC n.a. N.N. Blokhin" of RMH Moscow
E. I Borisova
FSBI "RORC n.a. N.N. Blokhin" of RMH Moscow
S. L Gutorov
FSBI "RORC n.a. N.N. Blokhin" of RMH Moscow
G. V Vyshinskaya
FSBI "RORC n.a. N.N. Blokhin" of RMH Moscow
References
- Luke J.J., Schwartz G.K. Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma. Clin. Dermatol. 2013;31(3): 290-97.
- Lves N.J., Stowe R.L., Lorigan P., Wheatley K. Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients. J. Clin. Oncol. 2007;25:5426-34.
- Alexandrov L.B. Nik-Zainal S., Wedge D.C., et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-21.
- Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P, Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A.; BRIM-3 Study Group. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N. Engl. J. Med. 2011;364(26):2507-16.
- Menzies A.M., Haydu L.E., Visintin L., Carlino M.S., Howle J.R., Thompson J.F., Kefford R.F., Scolyer R.A., Long G.V. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 2012;18:3242-49.
- Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010;363:809-19.
- Ribas A., Kim K.B., Schuchter L.M., et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutationpositive melanoma. J. Clin. Oncol. 2011;29(Suppl):8509. abstr.
- McArthur G.A., Chapman P.B., Robert C., Larkin J., Haanen J.B., Dummer R., Ribas A., Hogg D., Hamid O., Ascierto P.A., Garbe C., Testori A., Maio M., Lorigan P., Lebbé C., Jouary T., Schadendorf D., O'Day S.J., Kirkwood J.M., Eggermont A.M., Dréno B., Sosman J.A., Flaherty K.T., Yin M., Caro I., Cheng S., Trunzer K., Hauschild A. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-32.
- Ribas A., Gonzalez R., Pavlick A., Hamid O., Gajewski T.F., Daud A., Flaherty L., Logan T., Chmielowski B., Lewis K., Kee D., Boasberg P., Yin M., Chan I., Musib L., Choong N., Puzanov I., McArthur G.A. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15:954-65.
- Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M., Mandalà M., Demidov L., Stroyakovskiy D., Thomas L., de la Cruz-Merino L., Dutriaux C., Garbe C., Sovak M.A., Chang I., Choong N., Hack S.P., McArthur G.A., Ribas A. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N. Engl. J. Med. 2014;371:1867-76.
- de la Cruz-Merino L., et al. Clinical features of cobimetinib (COBI) - associated serous retinopathy (SR) in BRAF-mutated melanoma patients (pts) treated in the coBRIM study. J. Clin. Oncol. 2015;33(suppl):abstr. 9033.
- Ascierto P.A., McArthur G.A,, Dréno B., Atkinson V., Liszkay G., Di Giacomo A.M., Mandalà M., Demidov L., Stroyakovskiy D., Thomas L., de la Cruz-Merino L., Dutriaux C., Garbe C., Yan Y., Wongchenko M., Chang I., Hsu J.J., Koralek D.O., Rooney I., Ribas A., Larkin J. Cobimetinib combined with vemurafenib in advanced BRAFV600 - mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248-60.
- Harding J.J., Catalanotti F., Munhoz R.R., Cheng D.T., Yaqubie A., Kelly N., McDermott G.C., Kersellius R., Merghoub T., Lacouture M.E., Carvajal R.D., Panageas K.S., Berger M.F., Rosen N., Solit D.B., Chapman P.B. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist. 2015;20(7):789-97.
- Ugurel S., Loquai C., Kähler K., Hasse lJ., Berking C., Zimmer L., Haubitz I., Satzger I., Müller-Brenne T., Mikhaimer N.C., Becker J.C., Kilian K.J., Schadendorf D., Heinzerling L., Kaatz M., Utikal J., Göppner D., Pföhler C., Pflugfelder A., Mössner R., Gutzmer R.; Dermatologic Cooperative Oncology Group (DeCOG). A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Ann Oncol. 2015;26(3):573-82.
- Massi D., Brusa D., Merelli B., Falcone C., Xue G., Carobbio A., Nassini R., Baroni G., Tamborini E., Cattaneo L., Audrito V., Deaglio S., Mandalà M. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann. Oncol. 2015;26:1980-87.
- Flaherty K.T., et al. ASCO Meeting, 2016.
- TCGA, Cell, 2015.
- Shi H., Hong A., Kong X., Koya R.C., Song C., Moriceau G., Hugo W., Yu C.C., Ng C., Chodon T., Scolyer R.A., Kefford R.F., Ribas A., Long G.V., Lo R.S. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014;4:69-79.
- Trunzer K., Pavlick A.C., Schuchter L., Gonzalez R., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., Kim K.B., Weber J.S., Hersey P., Long G.V., Lawrence D., Ott P.A., Amaravadi R.K., Lewis K.D., PuzanovI., Lo R.S., Koehler A., Kockx M., Spleiss O., Schell-Steven A., Gilbert H.N., Cockey L., Bollag G., Lee R.J., Joe A.K., Sosman J.A., Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 2013;31:1767-74.
- Paraiso K., Fedorenko I.V., Cantini L.P., Munko A.C., Hall M., Sondak V.K., Messina J.L., Flaherty K.T., Smalley K.S. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer. 2010;102: 1724-30.
- Long G.V., et al. J. Clin.Oncol.2014;32(5S):9011.
- Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M., Mandalà M., Demidov L., Stroyakovskiy D., Thomas L., de la Cruz-Merino L., Dutriaux C., Garbe C., Sovak M.A., Chang I., Choong N., Hack S.P., McArthur G.A., Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014;371:1867-76.